Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Total Current Liabilities (2022 - 2025)

Gossamer Bio's Total Current Liabilities history spans 4 years, with the latest figure at $63.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 40.94% year-over-year to $63.4 million; the TTM value through Dec 2025 reached $63.4 million, up 40.94%, while the annual FY2025 figure was $63.4 million, 40.94% up from the prior year.
  • Total Current Liabilities reached $63.4 million in Q4 2025 per GOSS's latest filing, up from $62.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $63.4 million in Q4 2025 to a low of $34.6 million in Q1 2022.
  • Average Total Current Liabilities over 4 years is $47.5 million, with a median of $46.7 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: decreased 19.62% in 2023, then surged 40.94% in 2025.
  • A 4-year view of Total Current Liabilities shows it stood at $49.2 million in 2022, then rose by 4.81% to $51.6 million in 2023, then dropped by 12.77% to $45.0 million in 2024, then skyrocketed by 40.94% to $63.4 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Total Current Liabilities are $63.4 million (Q4 2025), $62.1 million (Q3 2025), and $53.6 million (Q2 2025).